Document is current
Any future updates will be listed below
-
Authors
Delrieu, Julien
Vellas, Bruno
Guyonnet, Sophie
Cantet, Christelle
Ovod, Vitaliy
Li, Yan
Bollinger, James
Bateman, Randall
Andrieu, Sandrine
,
Carrié, Isabelle
Brigitte, Lauréane
Faisant, Catherine
Lala, Françoise
Villars, Hélène
Combrouze, Emeline
Badufle, Carole
Zueras, Audrey
Morin, Christophe
Van Kan, Gabor Abellan
Dupuy, Charlotte
Rolland, Yves
Caillaud, Céline
Ousset, Pierre-Jean
Willis, Sherry
Belleville, Sylvie
Gilbert, Brigitte
Fontaine, Francine
Dartigues, Jean-François
Marcet, Isabelle
Delva, Fleur
Foubert, Alexandra
Cerda, Sandrine
Marie-Noëlle-Cuffi,
Costes, Corinne
Rouaud, Olivier
Manckoundia, Patrick
Quipourt, Valérie
Marilier, Sophie
Franon, Evelyne
Bories, Lawrence
Pader, Marie-Laure
Basset, Marie-France
Lapoujade, Bruno
Faure, Valérie
Tong, Michael Li Yung
Malick-Loiseau, Christine
Cazaban-Campistron, Evelyne
Desclaux, Françoise
Blatge, Colette
Dantoine, Thierry
Laubarie-Mouret, Cécile
Saulnier, Isabelle
Clément, Jean-Pierre
Picat, Marie-Agnès
Bernard-Bourzeix, Laurence
Willebois, Stéphanie
Désormais, Iléana
Cardinaud, Noëlle
Bonnefoy, Marc
Livet, Pierre
Rebaudet, Pascale
Gédéon, Claire
Burdet, Catherine
Terracol, Flavien
Pesce, Alain
Roth, Stéphanie
Chaillou, Sylvie
Louchart, Sandrine
Sudres, Kristel
Lebrun, Nicolas
Barro-Belaygues, Nadège
Touchon, Jacques
Bennys, Karim
Gabelle, Audrey
Romano, Aurélia
Touati, Lynda
Marelli, Cécilia
Pays, Cécile
Robert, Philippe
Le Duff, Franck
Gervais, Claire
Gonfrier, Sébastien
Gasnier, Yannick
Bordes, Serge
Begorre, Danièle
Carpuat, Christian
Khales, Khaled
Lefebvre, Jean-François
El Idrissi, Samira Misbah
Skolil, Pierre
Salles, Jean-Pierre
Coley, Nicola
- License Information
-
More Information
Article History
Received: 1 August 2023
Accepted: 5 October 2023
First Online: 23 October 2023
Declarations
:
: MAPT study protocol was approved by the French Ethics Committee in Toulouse (CPP SOOM II) and AFSSAPS (national agency for the safety of drugs and health products). All MAPT participants gave written informed consent at baseline visit. Participants in MAPT-PLUS gave separate written consent for clinical follow-up.
: Not applicable.
: JD has received payment/honoraria from Biogen (presentation for Biogen in 2021); and has participated on a Data Safety Monitoring Board or Advisory Board for French board for Roche in 2020–2022. SA has received grants from Europe, Ipsen, and France Alzheimer’s, served as a consultant for Ipsen, Pierre Fabre, Lilly, Nestlé, Sanofi, and Servier, and received non-financial support from Biogen, Nutrition Santé, Pfizer, and Icon, and other forms of support from the AMPA Association. BV receives grants from Pierre Fabre, Avid, Exonhit, AbbVie, Lilly, Lundbeck, MSD, Otsuka, Regeneron, Sanofi, Roche, AstraZeneca, LPG Systems, Nestlé, and Alzheon, and personal fees from Lilly, Lundbeck, MSD, Otsuka, Roche, Sanofi, Biogen, Nestlé, Transition Therapeutics, and Takeda. Washington University and Randall Bateman have equity ownership interest in C2N Diagnostics and receive income based on technology (blood plasma assay) licensed by Washington University to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with RJB as co-inventor, has submitted the US nonprovisional patent application “Plasma Based Methods for Determining A-Beta Amyloidosis.” RJB has received honoraria as a speaker/consultant/advisory board member from Amgen, AC Immune, Eisai, Hoffman-LaRoche, and Janssen; and reimbursement of travel expenses from AC Immune, Hoffman-La Roche and Janssen. All the other authors declare no competing interests.
